- Personal FinanceCompare Online BrokersTop StocksAlternative Investing
- CryptoGet StartedNFTs
Ultragenyx Pharmaceutical (NASDAQ:RARE), Quotes and News Summary
Ultragenyx Pharmaceutical (NASDAQ: RARE)
Earnings
see more| Q2 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-08-01 | ||||||
| REV | |||||||
| Q1 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -1.760 | -2.190 | -0.4300 | ||||
| REV | 83.650M | 79.935M | -3.715M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Ultragenyx Pharmaceutical Questions & Answers
You can purchase shares of Ultragenyx Pharmaceutical (NASDAQ: RARE) through any online brokerage.
Other companies in Ultragenyx Pharmaceutical’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Ultragenyx Pharmaceutical (NASDAQ: RARE) was reported by Stifel on Friday, July 1, 2022. The analyst firm set a price target for 142.00 expecting RARE to rise to within 12 months (a possible 126.66% upside). 15 analyst firms have reported ratings in the last year.
The stock price for Ultragenyx Pharmaceutical (NASDAQ: RARE) is $62.65 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical’s Q2 earnings are confirmed for Monday, August 1, 2022.
There is no upcoming split for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.